Chronic Unpredictable Stress Drives Non-pathological, Adaptive Metabolic Hormone Reprogramming with Reduced Insulin Resistance Linked to Depressive-like Behaviors

Abstract Major Depressive Disorder (MDD) is increasingly conceptualized as a neuroimmune-metabolic-oxidative stress (NIMETOX) condition, partly driven by environmental stressors. While new antidepressant strategies have emerged to target NIMETOX pathways, the mechanism by which chronic stress reshapes metabolic regulation-particularly in the absence of clinically overt metabolic disease-remain poorly understood. Using a 6-week chronic unpredictable mild stress (CUMS) paradigm in metabolically healthy male and female mice, we evaluated depressive-like behaviors alongside circulating glucose and metabolic hormones, including insulin, resistin, Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1), glucagon, ghrelin, leptin, and Plasminogen Activator Inhibitor-1 (PAI-1). We further assessed whether simvastatin, curcumin, S-adenosyl methionine (SAMe), or pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, normalize CUMS-induced metabolic and behavioral alterations, using fluoxetine as a reference antidepressant. CUMS induced a hypoinsulinemic state accompanied by enhanced basal insulin sensitivity and reduced insulin resistance, while central appetite regulation and adipose inflammatory profiles remained preserved. Indices of lower insulin resistance were strongly associated with sucrose preference and immobility time. Glucagon and PAI-1 showed positive associations with novel object recognition performance, whereas GIP and leptin were inversely related to open-field activity. Glucose levels correlated positively with rearing behavior. Despite significant improvements in depressive-like behaviors, none of the pharmacological interventions normalized the stress-induced metabolic hormone profile. Marked sex differences were observed, with females displaying a catabolic, immune-ready phenotype and males showing a relative anabolic bias. These findings indicate that CUMS induces a non-pathological, adaptive metabolic hormone reprogramming rather than metabolic dysfunction, supporting the interpretation of stress-related metabolic changes as resilient adaptations within the NIMETOX framework.